ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Swiss drug services firm Lonza has agreed to acquire a biologic facility in Vacaville, California, owned by Roche’s Genentech unit for $1.2 billion in cash. The facility, deemed one of the largest in the world for biologic manufacturing, has a bioreactor capacity of about 330,000 L. Lonza will invest an additional $560 million to upgrade the site. In the future, Lonza will supply Roche products currently manufactured at the site.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X